contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analytiker

Anton Damstén

SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen prob som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.

SciBasen Q3:n tiimoilta nyt myös video ulkona                    Inderes              SciBase Q3’24: Waiting for the clear waters - Inderes    Time: 14.11.2024 klo 14.09 SciBase kept building its commercial momentum in the US, where it achieved strong revenue growth in Q3. Yet, the major news of the day was the large capital raise, which would carry the company to cash flow positivity.                             Content:  00:00 Intro  00:12 Summary of Q3  01:47 US market  05:08 Financial situation and warrants  10:20 Positive drivers and risks

Tässä on Luiron tuore yhtiöraportti SciBasesta.  SciBase kasvoi vahvasti USAssa Q3 aikana, mutta päivän suurin uutinen oli suuri “pääomanhankinta”, jonka odotetaan tukevan kassavirran kääntymistä positiiviseksi. SciBase kept building its commercial momentum in the US where it achieved strong revenue growth in Q3 from low levels. Yet, the major news of the day was the large capital raise, which according to our current assumptions would carry the company to cash flow positivity. After adjusting for the capital raise, the risk/reward is starting to improve but is not yet looking attractive enough as we also expect the rights issue to put downward pressure on the share. We adjust our target price to SEK 0.45 per share (was 0.40) and reiterate our Reduce recommendation.                   Inderes              SciBase Q3'24: Approaching a turning point - Inderes    SciBase kept building its commercial momentum in the US where it achieved strong revenue growth in Q3 from low levels. Yet, the major news of the day was the large capital raise, which according to our current assumptions would carry the company to...

SciBase on solminut yhteistyön Seraly Dermatologyn kanssa Pittsburghissa.   Ja alla on Antin kommentit siitä.  Asiakas integroi useita Nevisense-järjestelmiä ihosyövän havaitsemisprosessiin. Seraly Dermatology vaikuttaa pieneltä toimijalta, mutta jokainen uusi asiakas vahvistaa Nevisense-tuotteen hyvää markkina-asemaa.                   Inderes              SciBase lands another customer in the US - Inderes    The announced partnership is with Seraly Dermatology in Pittsburgh, Pennsylvania. Each customer win is a sign that the market response to Nevisense remains good and that the product continues to be well positioned.

Yhdysvaltalainen asiantuntijapaneeli on arvioinut uusia melanoomadiagnostiikan teknologioita ja todennut, että Nevisensen tekoälypohjainen ratkaisu parantaa merkittävästi varhaista havaitsemista. SciBasen osakkeeseen liittyvät epävarmuudet koskevat vakuutuskattavuuden laajentumisen aikataulua ja teknologian omaksumista, mutta Inderesin näkemys ei muuttunut yhtiöstä.                   Inderes              SciBase receives validation for Nevisense from key opinion leaders in the US ...    A US expert consensus panel has reviewed new technologies available for melanoma, reviewing results presented in 19 articles. The report by top US clinicians concluded that Nevisense's AI-driven technology can significantly improve the early...

Antin etkokommentit, kun Scibase julkaisee keskiviikkona Q2-rapsansa.  We expect revenue to have continued to grow well at a still low absolute level, with profits continuing to fall further into the red. Once again, we’re looking forward to any additional visibility on commercialization progress and timelines, especially in the US, as we see this as a key driver for achieving cash flow neutrality and reducing the risks of the investment case. With the successful capital raise in the spring, the company’s near-term funding needs are covered, but an update on the burn rate and funding runway is still interesting as further capital is likely to be raised in about 6 months.                   Inderes              SciBase Q2’24 earnings preview: USA on our mind - Inderes    Once again, we're looking forward to any additional visibility on commercialization progress and timelines, especially in the US, as we see this as a key driver for achieving cash flow neutrality and reducing the risks of the investment case.

SciBase löytänyt tiensä telkkariin jenkeissä:                   NBC Los Angeles              Mole or skin cancer? A new device is making detection easier than ever &...    California Live’s Jessica Vilchis closes out Skin Cancer Awareness Month with dermatologist Dr. Glynis Ablon to talk about startling statistics about America’s most common cancer and the key things to look for. Plus, Dr. Ablon shares a new...

Osaako joku neuvoa, mikä tuo turbowarrantti on tikkeriltään? Eli se, jonka kaltaiset saavat leijonanosan tulevaisuuden arvonluonnista? Näkyy olevan melkoinen kasa eri instrumentteja Nordnetissa.

Scibase Holding

The capital raise announced on Friday reduces the financing risks and secures the company’s financing until early 2025. We expect the raise to succeed. With short-term funding in check, SciBase can focus again on executing its growth strategy in US, where clear signs of success could be emerging starting in 2025.

<p>The capital raise announced on Friday reduces the financing risks and secures the company&rsquo;s financing until early 2025. We expect the raise to succeed. With short-term funding in check, SciBase can focus again on executing its growth strategy in US, where clear signs of success could be emerging starting in 2025. We highlight the special situation of the stock due to the upcoming ex-unit right date and the very large number of warrants.</p>

	2023	24e	25e
Omsättning	23,2	31,9	50,4
tillväxt-%	29,94 %	37,33 %	57,94 %
EBIT (adj.)	−53,9	−56,1	−46,9
EBIT-%	−232,04 %	−175,89 %	−93,11 %
EPS (adj.)	−0,51	−0,24	−0,20
Utdelning	0,00	0,00	0,00
Direktavkastning
P/E (just.)	-	-	-
EV/EBITDA	-	-	-

Back to business

Login required

Scibase Holding

Key Estimate Figures11.04.

Login required

Scibase Holding

Key Estimate Figures11.04.

Beställ vårt nyhetsbrev — inget användarkonto krävs!